The Diffuse Large B-cell Lymphoma market report also offers comprehensive insights into the Diffuse Large B-cell Lymphoma market size, share, Diffuse Large B-cell Lymphoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Diffuse Large B-cell Lymphoma market size growth forward.
Some of the key highlights from the Diffuse Large B-cell Lymphoma Market Insights Report:
-
Several key pharmaceutical companies, including Calithera Biosciences, IMV, Roche, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, AbbVie, Genmab, Merck, Xencor, Janssen, Denovo Biopharma, Takeda, Gilead Sciences, AstraZeneca, and others, are developing novel products to improve the Diffuse Large B-cell Lymphoma treatment outlook.
-
In January 2025, Roche announced that it received 510(k) clearance from the U.S. FDA for its VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail, a highly sensitive in-situ hybridization (ISH) test. This test helps pathologists differentiate between B-cell malignancies and normal reactive responses to infections, enabling faster treatment decisions. This follows the CE Mark approval of the assay in June 2024.
-
In September 2023, AbbVie revealed that the European Commission (EC) granted conditional marketing authorization for TEPKINLY (epcoritamab) as a monotherapy for treating adult patients with relapsed or refractory (R/R) DLBCL after two or more lines of systemic therapy. TEPKINLY is the first and only subcutaneous T-cell engaging bispecific antibody approved for this patient group in the European Union (EU).
-
In June 2023, Genentech announced that the U.S. FDA approved COLUMVI (glofitamab) for treating adult patients with R/R DLBCL, including large B-cell lymphoma (LBCL) originating from follicular lymphoma, after two or more lines of systemic therapy. This approval was granted under accelerated approval based on response rate and durability of response in the Phase I/II NP30179 study.
-
In May 2023, the U.S. FDA granted accelerated approval for EPKINLY (epcoritamab) to treat patients with R/R DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
-
In 2023, the total market size for Diffuse Large B-Cell Lymphoma (DLBCL) in the 7MM was approximately USD 3,900 million. Salvage chemotherapy as a bridge to autologous stem cell transplant (SCT) remains the standard treatment for relapsed DLBCL, showing success in 30-40% of patients. Among the 7MM countries, the United States had the largest market size for DLBCL.
-
Despite being an aggressive form of lymphoma, DLBCL is considered potentially curable. Although it can occur in children, the incidence generally increases with age, and most patients are over 60 at the time of diagnosis. Approximately 30-40% of DLBCL patients are diagnosed with localized, stage I or II disease, while the remainder presents with widespread disease that has spread to areas like the spleen, liver, or bone marrow.
-
In 2023, there were about 76,100 new cases of DLBCL in the 7MM, with numbers expected to rise by 2034. Males are more commonly affected by DLBCL than females.
-
Current challenges in DLBCL research include accurately identifying molecular subsets and determining if specific chemotherapy regimens and targeted therapies provide differential benefits. The ultimate aim is to maximize cure rates while improving long-term survival and minimizing toxicity.
-
Several targeted therapies, cell therapies, and gene therapies are undergoing clinical evaluation for DLBCL, with some showing promising early results. In recent years, the US FDA has approved a variety of new treatments for relapsed/refractory DLBCL, including CAR-T therapies, small molecules, monoclonal antibodies, and antibody-drug conjugates. R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) is the most commonly used frontline regimen for DLBCL patients.
-
Approved drugs for treating Diffuse Large B-Cell Lymphoma include RITUXAN/MABTHERA (rituximab), YESCARTA (axicabtagene ciloleucel), KYMRIAH (tisagenlecleucel), XPOVIO (selinexor), POLIVY (polatuzumab vedotin-piiq), KEYTRUDA (pembrolizumab), COLUMVI (glofitamab), EPKINLY (epcoritamab), and others.
-
As per DelveInsight analysis, the Diffuse Large B-cell Lymphoma market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Diffuse Large B-cell Lymphoma Market Landscape
Diffuse Large B-cell Lymphoma Overview
Diffuse Large B-cell Lymphoma (DLBCL) is a fast-growing and aggressive form of Non-Hodgkin’s lymphoma, which is the most common type. It can develop in lymph nodes or outside the lymphatic system, such as in the gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain. One of the first signs of DLBCL is painless, rapid swelling in areas like the neck, underarms, or groin due to enlarged lymph nodes. DLBCL can be categorized based on molecular differences into three subtypes, depending on the cell of origin: germinal center B-cell (GCB) and activated B-cell (ABC or Non-GCB Subtype). It can also be classified based on the site of presentation (e.g., Primary CNS DLBCL, Primary cutaneous DLBCL, Intravascular large B-cell lymphoma) and stage (Localized or Advanced). Rare subtypes include primary mediastinal large B-cell lymphoma and primary effusion lymphoma (PEL).
Diagnosis of DLBCL is typically confirmed through an excisional biopsy of a suspicious lymph node, where large cell sheets that disrupt the follicle center are observed, and the cells stain positive for pan-B-cell markers like CD20 and CD79a. The cell of origin (COO) is identified using immunohistochemical stains, while molecular features such as double-hit or triple-hit disease are determined by fluorescent in situ hybridization (FISH). Currently, commercial tests for commonly occurring mutations are not routinely used to guide treatment decisions. A tissue biopsy remains essential for a definitive DLBCL diagnosis.
Do you know the treatment paradigms for different countries? Download our Diffuse Large B-cell Lymphoma Market Sample Report
Diffuse Large B-cell Lymphoma Epidemiology Insights
-
DelveInsight estimates that in 2023, there were approximately 17,000 cases of DLBCL in males in the United States.
-
The highest number of DLBCL patients in the U.S. is found in the 65–74 age group, while the lowest number is in the 0–19 age group.
Diffuse Large B-cell Lymphoma Epidemiology Segmentation
DelveInsight’s Diffuse Large B-cell Lymphoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Diffuse Large B-cell Lymphoma historical patient pools and forecasted Diffuse Large B-cell Lymphoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Diffuse Large B-cell Lymphoma Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Diffuse Large B-cell Lymphoma Prevalence
-
Age-Specific Diffuse Large B-cell Lymphoma Prevalence
-
Gender-Specific Diffuse Large B-cell Lymphoma Prevalence
-
Diagnosed and Treatable Cases of Diffuse Large B-cell Lymphoma
Visit for more @ Diffuse Large B-cell Lymphoma Epidemiological Insights
Diffuse Large B-cell Lymphoma Market Outlook
The growth of the Diffuse Large B-cell lymphoma (DLBCL) market during the forecast period is being driven by an increase in pipeline candidates aimed at developing better therapies for DLBCL recovery. The approval of Rituximab has significantly changed the landscape of DLBCL treatment. For patients with DLBCL, chemoimmunotherapy remains the standard of care. Additionally, the approval of several new drugs has transformed the treatment approach for patients with relapsed or refractory (R/R) DLBCL in the second and third lines of treatment.
One of the most commonly used frontline regimens is R-CHOP, which combines rituximab with chemotherapy drugs (cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone), typically administered every three weeks for a total of six cycles.
Leading companies in the DLBCL field, including Denovo Biopharma, AstraZeneca, Merck, and others, are evaluating their lead candidates in various stages of clinical development.
Diffuse Large B-cell Lymphoma Marketed Drugs
-
YESCARTA (axicabtagene ciloleucel): Kite (Gilead Sciences)
-
EPKINLY (epcoritamab): Genmab and AbbVie
Diffuse Large B-cell Lymphoma Emerging Drugs
-
Enzastaurin (DB102): Denovo Biopharma
-
Zilovertamab Vedotin: Merck
Diffuse Large B-cell Lymphoma Key Companies
-
Calithera Biosciences, IMV, Roche, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, AbbVie, Genmab, Merck, Xencor, Janssen, Denovo Biopharma, Takeda, Gilead Sciences, AstraZeneca, and others
For more information, visit Diffuse Large B-cell Lymphoma Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Diffuse Large B-cell Lymphoma Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Diffuse Large B-cell Lymphoma, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Diffuse Large B-cell Lymphoma epidemiology in the 7MM
-
Diffuse Large B-cell Lymphoma marketed and emerging therapies
-
Diffuse Large B-cell Lymphoma companies
-
Diffuse Large B-cell Lymphoma market drivers and barriers
Table of Contents:
1 Diffuse Large B-cell Lymphoma Market Key Comprehensive Insights
2 Diffuse Large B-cell Lymphoma Market Report Introduction
3 Competitive Intelligence Analysis for Diffuse Large B-cell Lymphoma
4 Diffuse Large B-cell Lymphoma Market Analysis Overview at a Glance
5 Executive Summary of Diffuse Large B-cell Lymphoma
6 Diffuse Large B-cell Lymphoma Epidemiology and Market Methodology
7 Diffuse Large B-cell Lymphoma Epidemiology and Patient Population
8 Diffuse Large B-cell Lymphoma Patient Journey
9 Diffuse Large B-cell Lymphoma Treatment Algorithm, Diffuse Large B-cell Lymphoma Current Treatment, and Medical Practices
10 Key Endpoints in Diffuse Large B-cell Lymphoma Clinical Trials
11 Diffuse Large B-cell Lymphoma Marketed Therapies
12 Diffuse Large B-cell Lymphoma Emerging Therapies
13 Diffuse Large B-cell Lymphoma: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Diffuse Large B-cell Lymphoma
16 Diffuse Large B-cell Lymphoma Market Key Opinion Leaders Reviews
18 Diffuse Large B-cell Lymphoma Market Drivers
19 Diffuse Large B-cell Lymphoma Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Diffuse Large B-cell Lymphoma Epidemiology 2034
DelveInsight’s “Diffuse Large B-cell Lymphoma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Diffuse Large B-cell Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diffuse Large B-cell Lymphoma Pipeline 2024
“Diffuse Large B-cell Lymphoma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diffuse Large B-cell Lymphoma market. A detailed picture of the Diffuse Large B-cell Lymphoma pipeline landscape is provided, which includes the disease overview and Diffuse Large B-cell Lymphoma treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/